Results 11 to 20 of about 98,807 (272)

Gemcitabine: Progress in the treatment of pancreatic cancer [PDF]

, 2001
Unresectable pancreatic cancer has a dismal prognosis with a median survival of 3-5 months in untreated disease. Since the introduction of gemcitabine, pancreatic cancer may no longer be regarded a chemotherapy-resistant tumor.
Heinemann, Volker
core   +1 more source

Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors

Journal of Pharmacological Sciences, 2015
Gemcitabine is widely used for pancreatic, lung, and bladder cancer. However, drug resistance against gemcitabine is a large obstacle to effective chemotherapy. Nucleoside transporters, nucleoside and nucleotide metabolic enzymes, and efflux transporters
Kentaro Minami, Yoshinari Shinsato, Masatatsu Yamamoto, Homare Takahashi, Shaoxuan Zhang, Yukihiko Nishizawa, Sho Tabata, Ryuji Ikeda, Kohich Kawahara, Kazutake Tsujikawa, Kazuo Chijiiwa, Katsushi Yamada, Shin-ichi Akiyama, Sandra Pérez-Torras, Marcal Pastor-Anglada, Tatsuhiko Furukawa, Takeda Yasuo   +16 more
doaj   +1 more source

Hsa-miR-3178/RhoB/PI3K/Akt, a novel signaling pathway regulates ABC transporters to reverse gemcitabine resistance in pancreatic cancer

Molecular Cancer, 2022
Background Although gemcitabine has been considered as the first-line drug for advanced pancreatic cancer (PC), development of resistance to gemcitabine severely limits the effectiveness of this chemotherapy, and the underlying mechanism of gemcitabine ...
Jianyou Gu, Wenjie Huang, Xianxing Wang, Junfeng Zhang, Tian Tao, Yao Zheng, Songsong Liu, Jiali Yang, Zhe-Sheng Chen, Chao-Yun Cai, Jinsui Li, Huaizhi Wang, Yingfang Fan   +12 more
doaj   +1 more source

Pharmacogenomics and gemcitabine

Annals of Oncology, 2006
Approximately half of lung cancer patients present with metastases, and a large proportion will develop recurrent disease, with median survival to cisplatin-based chemotherapy of 11 months. No predictive factor of response to cisplatin-based chemotherapy is yet available in clinical practice.
R, Rosell, M, Cobo, D, Isla, C, Camps, B, Massuti   +4 more
openaire   +2 more sources

Role of gemcitabine in the treatment of advanced and metastatic breast cancer [PDF]

, 2003
Gemcitabine is an antimetabolite drug with proven antitumor activity and tolerability in metastatic breast cancer. In a total of nine studies, gemcitabine monotherapy has reached response rates of up to 37% in the first-line setting, 26% in the second ...
Heinemann, Volker
core   +1 more source

Gemcitabine and carboplatin in intensively pretreated patients with metastatic breast cancer [PDF]

, 2007
Background: Patients with metastatic breast cancer (MBC) are increasingly exposed to anthracyclines and taxanes either during treatment of primary breast cancer or during initial therapy of metastatic disease.
Vehling-Kaiser, U., Melchert, F., Koelbl, H., Maubach, P., Stemmler, H. J., Scharl, A., Heinemann, Volker, Weber, B., Meerpohl, H., Kalischefski, B., Laessig, D., Stauch, M., Morack, G., Fasching, P. A.   +13 more
core   +1 more source

Stearoyl-CoA desaturase 1 inhibitor supplemented with gemcitabine treatment reduces the viability and fatty acid content of pancreatic cancer cells in vitro

Journal of Pancreatology, 2021
. Objective:. Pancreatic cancer (PC) is an aggressive cancer with ineffective treatment. Inhibition of stearoyl-CoA desaturase 1 (SCD1) suppresses cancer proliferation and might act as a novel chemotherapy supplement, but this has not been investigated ...
Amon B. Hackney, Wen Y. Chung, John Isherwood, Ashley R. Dennison, Naomi Martin   +4 more
doaj   +1 more source

A rapid and systematic review of the clinical effectiveness and cost effectiveness of gemcitabine for the treatment of pancreatic cancer [PDF]

, 2001
Background Pancreatic cancer is the eighth most common cancer in the UK and the sixth most common cause of cancer death; in 1998, 3198 men and 3364 women died from this condition. In an average health authority with a population of 500,000, there
Calvert, N, Larvin, M., E. Morris, Bansback, N., Bansback, N, D. Radstone, Morris, E., D. Forman (12595714), A. Crellin (12595711), S. Ward (7130246), Forman, D., E. Morris (7786319), N. Calvert, Calvert, N., D. Radstone (12595720), Crellin, A., Larvin, M, Morris, E, D. Forman, Ward, S., A. Crellin, Radstone, D, S. Ward, N. Calvert (12595708), M. Larvin, N. Bansback (12595705), Forman, D, Ward, S, N. Bansback, Michael Larvin (12595717), Crellin, A   +30 more
core   +1 more source

A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer [PDF]

, 2006
Background Anti-angiogenic treatment is believed to have at least cystostatic effects in highly vascularized tumours like pancreatic cancer. In this study, the treatment effects of the angiogenesis inhibitor Cilengitide and gemcitabine were compared with
Castellano Daniel, Kleeff Jörg, Vermorken Jan, Albert Abad Esteve, Simon van Belle, CASTELLANO, D, STOGER, H, Esteve, Albert Abad, Jochen Raedle, HERZOG, P, DAVIDSON, N, OETTLE, H, Balcke, Peter, SCHEITHAUER, W, DOBROWOLSKI, F, TEMPIA-CALIERA, AA, Neville Davidson, Langrehr, Jan M., Herzog Peter, Scheithauer Werner, Friess Helmut, HOSSFELD, DK, KOVAR, A, Herbert Stöger, Adrien A Tempia-Caliera, Jan M Langrehr, Neyns Bart, Bart Neyns, Castellano, Daniel, Oettle Helmut, Herzog, Peter, BALCKE, P, Dittrich, Christian, KATZ, F, Katz Frieder, Robert Hawkins, Hawkins Robert, Raedle, Jochen, PIEDBOIS, P, LANGREHR, JM, Pascal Piedbois, Werner Scheithauer, Dobrowolski, Frank, NIEDERGETHMANN, M, Nippgen Johannes, Hawkins, Robert, Van Belle, Simon, Piedbois Pascal, Raedle Jochen, Andreas Kovar, RAEDLE, J, HAWKINS, R, Stöger Herbert, Peter Balcke, Davidson, Neville, Tempia-Caliera, Adrien A., DITTRICH, C, Christian Dittrich, Hossfeld Dieter K, Tempia-Caliera Adrien A, Helmut Oettle, NIPPGEN, J, Esteve Albert, ESTEVE, AA, Balcke Peter, Friess, Helmut, Katz, Frieder, Oettle, Helmut, Hossfeld, Dieter K., Dobrowolski Frank, Peter Herzog, Daniel Castellano, Kleeff, Jörg, Niedergethmann Marco, Marco Niedergethmann, Dieter K Hossfeld, Jan Vermorken, Scheithauer, Werner, KLEEFF, J, Helmut Friess, Nippgen, Johannes, NEYNS, B, Jörg Kleeff, Dittrich Christian, Langrehr Jan M, Davidson Neville, Stöger, Herbert, Frank Dobrowolski, Frieder Katz, Kovar, Andreas, Johannes Nippgen, van Belle Simon, Niedergethmann, Marco, Vermorken, Jan, Kovar Andreas, FRIESS, H, Piedbois, Pascal, Neyns, Bart, VERMORKEN, J   +98 more
core   +1 more source

Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin? [PDF]

, 2003
Background: Serial kinetics of serum CA 19-9 levels have been reported to reflect response and survival in patients with pancreatic cancer undergoing surgery, radiotherapy, and chemotherapy.
Stoffregen, C., Stemmler, J., Wilkowski, R., Garbrecht, M., Schalhorn, A., Lamerz, Rolf, Stieber, P., Szymala, A. M., Schermuly, M. M., Heinemann, Volker, Helmberger, T., Niebler, K.   +11 more
core   +1 more source